Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: A subgroup analysis of a randomized trial

Annals of Internal Medicine

Volumn 158, Issue 12, 2013, Pages 861-868

  Mahaffey, Kenneth W ^a   Wojdyla, Daniel ^a   Hankey, Graeme J ^b   White, Harvey D ^c   Nessel, Christopher C ^d   Piccini, Jonathan P ^a   Patel, Manesh R ^a   Berkowitz, Scott D ^e   Becker, Richard C ^a   Halperin, Jonathan L ^f   Singer, Daniel E ^g   Califf, Robert M ^h   Fox, Keith A A ⁱ   Breithardt, Günter ^j   Hacke, Werner ^k  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^e BAYER CORPORATION   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF EDINBURGH   (United Kingdom)

^j UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^k UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; RIVAROXABAN; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; COMPARATIVE EFFECTIVENESS RESEARCH; EMBOLISM; FACTOR XA; FEMALE; HEMORRHAGE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MORPHOLINES; STROKE; THIOPHENES; TREATMENT OUTCOME; VITAMIN K; WARFARIN;

EID: 84879169090     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-158-12-201306180-00003     Document Type: Article

References (13)

1. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, et al; ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903-1912. [PMID: 16765759]
2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151. [PMID: 19717844]
3. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159:340-347. [PMID: 20211293]
4. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891. [PMID: 21830957]
5. del Zoppo GJ, Eliasziw M. New options in anticoagulation for atrial fibrillation [Editorial]. N Engl J Med. 2011;365:952-953. [PMID: 21830960]
6. Rose A. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation [Letter]. N Engl J Med. 2011;365:2333-2334. [PMID: 22168651]
7. Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika. 1993;80:557-572.
8. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992. [PMID: 21870978]
9. Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J, et al; RE-LY Steering Committee and Investigators. Dabigatran and warfarin in vitamin K antagonist-naive andexperienced cohorts with atrial fibrillation. Circulation. 2010;122:2246-53. [PMID: 21147728]
10. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689-2696. [PMID: 17515465]
11. Fang MC, Go AS, Hylek EM, Chang Y, Henault LE, Jensvold NG, et al. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc. 2006;54:1231-1236. [PMID: 16913990]
12. Raunsø J, Selmer C, Olesen JB, Charlot MG, Olsen AM, Bretler DM, et al. Increased short-term risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation. Eur Heart J. 2012;33:1886-1892. [PMID: 22199117]
13. Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009;15:244-252. [PMID: 19326955]